Loading...
01/11 11:24
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary and Q&A indicate positive sentiment, driven by raised revenue guidance, strong growth in TissueCypher and DecisionDx-Melanoma tests, and optimistic future cash flow expectations. Despite some uncertainties in FDA submission timelines and reimbursement pathways, the overall outlook is upbeat. The company's strategic initiatives and growth potential in the GI space further bolster confidence. The market is likely to react positively, with stock price expected to rise by 2% to 8% over the next two weeks.
Revenue $86.2 million, a decrease of $0.8 million or 1% year-over-year. The decrease was due to a $12.5 million drop in revenue from dermatological tests, offset by an $11.7 million increase in revenue from non-dermatological tests.
Gross Margin 77.3%, down from 80.7% year-over-year. Adjusted gross margin was 79.5%, down from 83.2%. The decline was attributed to higher personnel costs, lab services, and lab supplies expenses.
Net Income $4.5 million, down from $8.9 million year-over-year. The decrease was due to higher operating expenses, including personnel costs and inflationary wage adjustments.
Adjusted EBITDA $10.4 million, down from $21.5 million year-over-year. The decline was due to increased operating expenses and lower gross margins.
Cash, Cash Equivalents, and Marketable Securities $275.9 million, reflecting a strong balance sheet to support growth initiatives.
Test Report Volume 26,574 tests, with core revenue drivers growing 33% year-over-year. DecisionDx-Melanoma tests increased 4% year-over-year, and TissueCypher tests grew 92% year-over-year.
Operating Expenses $90.4 million, up from $82 million year-over-year. The increase was driven by higher sales and marketing expenses, general and administrative expenses, and cost of sales.
DecisionDx-Melanoma: Delivered 9,981 test reports in Q2 2025, a 16% sequential increase from Q1 2025 and a 4% year-over-year increase from Q2 2024. Associated with a 32% reduction in mortality risk compared to untested patients.
DecisionDx-SCC: Delivered 4,762 test reports in Q2 2025. Reimbursement challenges due to noncoverage policy effective April 24, 2025. Reconsideration request submitted to Novitas and MolDx.
TissueCypher: Delivered 9,170 test reports in Q2 2025, a 92% year-over-year growth from Q2 2024. Growth driven by unmet clinical need and commercial optimization.
Atopic Dermatitis Diagnostic Test: Collaboration with SciBase to develop a diagnostic test for predicting flares in atopic dermatitis patients. Internally developed pipeline test validated to predict treatment responses for moderate to severe atopic dermatitis. Expected launch by end of 2025.
Revenue Guidance: Raised 2025 revenue guidance to $310-$320 million, up from $287-$297 million. Normalized revenue growth excluding DecisionDx-SCC is estimated at 21%-26%.
Previse Acquisition: Acquisition aims to enhance gastrointestinal offerings, including multi-omics approach for Barrett's esophagus and non-endoscopic sample collection device.
Financial Performance: Q2 2025 revenue of $86.2 million, a 1% decrease year-over-year. Dermatological test revenue decreased by $12.5 million, while non-dermatological test revenue increased by $11.7 million. Gross margin at 77.3%.
Cash Position: Ended Q2 2025 with $275.9 million in cash, cash equivalents, and marketable securities. Positive net cash flow from operations expected for 2025.
M&A Strategy: Focused on complementing existing portfolio, diversifying test portfolio and payer mix, and ensuring transactions support profitable growth.
SciBase Collaboration: Collaboration to develop diagnostic tests for atopic dermatitis using advanced EIS technology.
DecisionDx-SCC Test Reimbursement: The Novitas Local Coverage Determination policy, effective April 24, 2025, included noncoverage language for the DecisionDx-SCC test. This has led to a significant decrease in revenue from dermatological tests, specifically impacting DecisionDx-SCC, which saw a $12.5 million revenue drop. The company has submitted a reconsideration request, but there is no specified timeline for a final decision, creating uncertainty.
Gross Margin Decline: Gross margin decreased from 80.7% in Q2 2024 to 77.3% in Q2 2025. Adjusted gross margin also declined from 83.2% to 79.5%. This decline is attributed to higher personnel costs, lab services, and lab supplies, reflecting increased test report volumes and inflationary wage adjustments.
Increased Operating Expenses: Operating expenses rose to $90.4 million in Q2 2025 from $82 million in Q2 2024. This increase is driven by higher sales and marketing expenses, general and administrative costs, and cost of sales, primarily due to headcount expansion, inflationary wage adjustments, and increased business development activities.
Regulatory and Reimbursement Risks: The company faces challenges in the dynamic reimbursement environment, particularly with the noncoverage decision for DecisionDx-SCC. This creates risks for revenue stability and growth, as well as potential delays in achieving reimbursement for new tests.
Pipeline and M&A Execution Risks: The company is investing in pipeline initiatives and M&A activities, such as the SciBase collaboration and Previse acquisition. However, these initiatives carry execution risks, including the potential for delays, unsuccessful validation, or failure to achieve expected returns.
Revenue Guidance for 2025: Castle Biosciences has raised its total revenue guidance for 2025 to a range of $310 million to $320 million, up from the previously provided range of $287 million to $297 million. This reflects adjustments for the DecisionDx-SCC LCD effective April 24, 2025. Excluding DecisionDx-SCC revenue, normalized revenue growth for 2025 is expected to be approximately 21% to 26%.
DecisionDx-Melanoma Volume Growth: The company expects high single-digit volume growth for DecisionDx-Melanoma for the full year 2025 compared to 2024.
TissueCypher Growth Drivers: Castle Biosciences anticipates continued strong growth for TissueCypher, driven by recognition of unmet clinical needs and commercial optimization efforts, including education and awareness.
Pipeline Test for Atopic Dermatitis: The company plans to launch a new pipeline test for atopic dermatitis by the end of 2025, which aims to predict treatment responses for patients eligible for systemic therapy.
Collaboration with SciBase: Castle Biosciences has entered into a collaboration with SciBase to develop a diagnostic test for predicting flares in atopic dermatitis patients, targeting a U.S. market of up to 24 million people.
Previse Acquisition and GI Offerings: The Previse acquisition is expected to enhance the company's gastrointestinal offerings, including a multi-omics approach for Barrett's esophagus and a non-endoscopic sample collection device for GI diseases.
The selected topic was not discussed during the call.
The earnings call presents mixed signals: positive revenue growth and pipeline developments are countered by declining margins, increased expenses, and a net loss. The raised revenue guidance is a positive sign, but the lack of clarity on reimbursement pathways and flat SCC volumes temper enthusiasm. The Q&A reveals some analyst concerns, particularly regarding reimbursement and FDA approval impacts. The absence of a market cap limits prediction accuracy, but the overall sentiment leans towards neutral, given the balancing of positive growth prospects against financial pressures and uncertainties.
The earnings call summary and Q&A indicate positive sentiment, driven by raised revenue guidance, strong growth in TissueCypher and DecisionDx-Melanoma tests, and optimistic future cash flow expectations. Despite some uncertainties in FDA submission timelines and reimbursement pathways, the overall outlook is upbeat. The company's strategic initiatives and growth potential in the GI space further bolster confidence. The market is likely to react positively, with stock price expected to rise by 2% to 8% over the next two weeks.
The earnings call presents mixed signals. Financial performance shows increased net loss and higher expenses, which are negative, but improved adjusted EBITDA is positive. The Q&A reveals cautious optimism with consistent growth for TissueCypher and strategic realignments. However, management's vague responses and lack of immediate revenue impact from acquisitions temper the outlook. The guidance for gross margins and revenue growth is moderate, with no major catalysts to significantly sway the stock price in either direction. Given these factors, a neutral stock price movement is expected over the next two weeks.
The company reported a significant increase in revenue and net income, transitioning from a net loss to a profit. Despite a slight decline in quarterly gross margins, full-year margins improved. The Q&A highlighted growth potential and strategic focus on existing and new verticals. While management avoided specifics on some issues, the overall financial performance and optimistic outlook, including a positive adjusted EBITDA forecast, suggest a positive sentiment. However, the lack of specific guidance on some metrics and potential reimbursement issues could temper enthusiasm, resulting in a moderate positive impact.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
